BDBM410358 2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymethyl)-1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,3-a][1,5]naphthyridin-9-yl)-4-methylphenyl)isonicotinamide and 2-(1,1-difluoroethyl)-N-(3-((4aS,5S)-5-(hydroxymethyl)-1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,3-a][1,5]naphthyridin-9-yl)-4-methylphenyl)isonicotinamide::US10377770, Example 118
SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2C[C@H](CO)[C@H]3COCCN3c2c1
InChI Key InChIKey=CTAJXKFOFSOHKM-NTKDMRAZSA-N
Data 1 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 1 hit for monomerid = 410358
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair